Medical News Summary: Statin drugs carry low risk of muscle damage leading to kidney failure


advertisement

About: Statin drugs carry low risk of muscle damage leading to kidney failure
Date: 22 November 2004
Source: Web MD Extra
Medical News Summary (summary of medical news story as reported by Web MD Extra): Confusion about drug safety has been reignited after a study released results that most statin drugs carried a low risk of a potentially lethal muscle disorder called rhabdomyolysis. The study involved statin the statin drugs Baycol, Lipitor, Pravachol and Zochor. Crestor was not tested as it became available only after the study had commenced. Baycol was removed from sale in 2001 following findings that it was allegedly responsible for 31 cases of rhabdomyolysis (muscle tissue disintegration leading to excess chemical released into bloodstream causing kidney failure) leading to death. The study found that 1 in 23,000 consumers of statin drugs developed rhabdomyolysis and Baycol increased the risk by ten times. A combination of statin drugs with other cholester-loweing drugs (eg Lopid, Tricor) resulted in 60 per 100,000 people developing rhabdomyolysis. Researchers believe that the risk may be much higher for older diabetics. FDA warnings about Crestor followed discoveries that it may be problematic for people with underactive thyroids, kidney problems and those over 65. Symptoms of rhabdomhyolyosis include muscle soreness and dark urine.
URL: http://www.cbsnews.com/stories/2004/11/22/health/webmd/main657021.shtml
Related Disease Topics: Rhabdomyolysis, Kidney failure, Muscle damage, Muscle disorder, Diabetes, High cholesterol, Underactive thyroid, Kidney problems
Related Symptom Topics: Muscle soreness, dark urine

Related Medical News Channels: This medical news summary article refers to the following medical channel categories:

Medical Tools & Articles:


Next articles:

Medical Articles:
 
 
CureResearch.comTM Copyright © 2010 Health Grades, Inc. All rights reserved.
Home | Contents | Search | Site Map | Feedback | Contact Us | Terms of Use | Privacy Policy | About Us | Advertise